Patients with abdominal bloating
Conditions
Interventions
Oral administration of Daikenchuto 15.0g/day for 4weeks.
Oral administration of Biofermin 3T/day for 4weeks.
Sponsors
Izumo-City General Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Self-reported abdominal bloating rating >= 4 20 <= years old <= 84 Male and female Outpatients Provides written informed consent
Exclusion criteria
Exclusion criteria: Patients receiving daikenchuto or other Japanese traditional herbal medicine within 4 weeks before enrolled in this study If not stable doses of the follow medications are taken for at least 2 weeks before enrolled to this study: acid suppressant, prokinetics, calcium polycarbophil, anticholinergic drug, laxative, antidepressant, anti-anxiety agent. Patients with organic lesion like cancer. Patients with serious coexisting disease (e.g. Hepatic, renal, cardiac, hematological, or metabolic disorder). Lactating or pregnant mother or women who wish to become pregnant during the study period. Determined not applicable for this study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Self-reported abdominal bloating rating | — |
Secondary
| Measure | Time frame |
|---|---|
| Self-reported satisfaction rating with treatment SF-8 GSRS Bristol stool scale Abdominal girth Rate of Sympathetic /parasympathetic Salivary amylase activity | — |
Countries
Japan
Contacts
Public ContactMika Yuki
Izumo-City General Medical Center Division of Internal Medicine
Outcome results
None listed